AccurKardia

AccurKardia

Software Development

New York, NY 1,419 followers

ECG-led Diagnostics

About us

AccurKardia is an ECG-led diagnostics software company transforming ECG signals into a broad biomarker and diagnostic tool for disease management in cardiology and beyond. Our mission is to improve patient outcomes and save lives on a global scale. Our flagship product, AccurECG™, is an FDA-cleared (Class II SaMD), cloud-based, device-agnostic software providing fully automated ECG interpretation, capable of detecting up to 13 arrhythmias. It assists cardiac monitoring companies in analyzing ECGs from holters, event recorders, and cardiac telemetry devices, significantly enhancing efficiency and patient care. Recently, AccurKardia reached a major milestone with the FDA Breakthrough Device Designation for our AI-driven ECG-based Aortic Valve Stenosis (AK-AVS) screening software. This achievement highlights our dedication to advancing early detection and precision medicine in cardiovascular care. We are also proud participants in the MedTech Innovator 2024 Cohort and the Heart & Brain Health Accelerator track, in collaboration with the American Heart Association’s Center for Health Technology and Innovation.

Industry
Software Development
Company size
11-50 employees
Headquarters
New York, NY
Type
Privately Held
Founded
2019
Specialties
artificial intelligence, AI, cardiac healthcare, ecg analysis, healthtech, medtech, IoT, digitalhealth, medical devices, remote patient monitoring, diagnostics, biomarker, and EKG

Locations

Employees at AccurKardia

Updates

Similar pages

Browse jobs

Funding